{
    "clinical_study": {
        "@rank": "70364", 
        "arm_group": [
            {
                "arm_group_label": "Paclitaxel Eluting Stent", 
                "arm_group_type": "Experimental", 
                "description": "Patients randomized to treatment with paclitaxel eluting stent will receive the Zilver\u00ae PTX\u00ae stent.Primary stenting should be performed covering the full lesion.  Post-dilatation is at the investigator's discretion."
            }, 
            {
                "arm_group_label": "Paclitaxel Eluting Balloon", 
                "arm_group_type": "Active Comparator", 
                "description": "For patients randomized to treatment with drug eluting balloon (DEB), angioplasty (ballooning) should be performed covering the full lesion."
            }
        ], 
        "brief_summary": {
            "textblock": "Objective of the REAL PTX trial is to compare paclitaxel-eluting stents to\n      paclitaxel-eluting balloons for treating symptomatic peripheral artery disease of the\n      femoropopliteal artery."
        }, 
        "brief_title": "Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Peripheral Artery Disease", 
        "condition_browse": {
            "mesh_term": "Peripheral Arterial Disease"
        }, 
        "detailed_description": {
            "textblock": "The REAL PTX trial has been designed as prospective, randomized, multi-center, post-market\n      study investigating the effect of the paclitaxel-eluting stent Zilver\u00ae PTX\u00ae (DES)in\n      comparison to the use of a paclitaxel eluting balloon (DEB)in treating symptomatic\n      peripheral artery disease of the femoropopliteal artery.\n\n      Up to 150 patients will be enrolled in Germany and Belgium.  Enrollment is expected to be\n      completed within approximately six months of initiating the study.\n\n      One group (DES or DEB) will be considered to yield significantly better results of the\n      primary patency rate than the other group at 12 months follow up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject age \u2265 18\n\n          -  Subject has been informed of the nature of the study, agrees to participate, and has\n             signed a Medical Ethics Committee approved consent form.\n\n          -  Subject understands the duration of the study, agrees to attend follow-up visits, and\n             agrees to complete the required testing.\n\n          -  Rutherford category 2-5.\n\n          -  Subject has a de novo or restenotic lesion with \u2265 70% stenosis documented\n             angiographically and no prior stent in the target lesion.\n\n          -  Target lesion is at least 1cm below the origin of the profunda femoris and does not\n             exceed the medial femoral epicondyle.\n\n          -  A single target lesion (stenotic areas separated by more than 3 cm with \u2264 30%\n             stenosis might, at the decision of the investigator, be considered as 2 lesions).\n\n          -  Reference vessel diameter (RVD) \u2265 4 mm and \u2264 6.5 mm by visual assessment.\n\n          -  Patency of at least one (1) infrapopliteal artery to the ankle (< 50% diameter\n             stenosis) in continuity with the native femoropopliteal artery.\n\n          -  A guidewire has successfully traversed the target treatment segment.\n\n        Exclusion Criteria:\n\n        Clinical exclusion criteria\n\n          -  Inability to obtain informed consent.\n\n          -  Life expectancy < 12 months.\n\n          -  Pregnancy, suspected pregnancy, or breastfeeding during study period (patients of\n             childbearing potential must have negative serum pregnancy test 7 days prior to\n             treatment).\n\n          -  Presence of one or more of the following co-morbid factors: hemodialysis dependence,\n             renal insufficiency with a serum creatinine \u2265 2.5 mg/dl, cerebrovascular accident\n             (CVA) within 1 month of procedure or any CVA resulting in unresolved walking\n             impairment, and/or myocardial infarction (MI) within 1 month of procedure.\n\n          -  Any evidence of hemodynamic instability prior to procedure/randomization.\n\n          -  Coagulopathy or clotting disorders.\n\n          -  Present or suspected systemic infection or osteomyelitis affecting target limb.\n\n          -  Contraindication to contrast media or any study-required medication (antiplatelets,\n             anticoagulants, thrombolytics, etc).\n\n          -  Hypersensitivity to nitinol and/or paclitaxel.\n\n          -  Enrollment into another study.\n\n          -  Intervention of the target lesion less than 90 days prior of the study procedure.\n\n        Anatomic Exclusion Criteria:\n\n          -  Untreated external iliac artery inflow lesion (study allows for successful treatment\n             prior to study treatment procedures).\n\n          -  Total occlusion uncrossable by a conventional guidewire.\n\n          -  Acute occlusive intraluminal thrombosis of the proposed lesion site.\n\n          -  Evidence of an aneurysm at the target lesion site.\n\n          -  Perforation in the target vessel as evidenced by the extravasation of contrast."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728441", 
            "org_study_id": "Prov 01-2012", 
            "secondary_id": "U1111-1136-8610"
        }, 
        "intervention": [
            {
                "arm_group_label": "Paclitaxel Eluting Stent", 
                "intervention_name": "Paclitaxel Eluting Stent", 
                "intervention_type": "Device", 
                "other_name": "Zilver PTX stent"
            }, 
            {
                "arm_group_label": "Paclitaxel Eluting Balloon", 
                "intervention_name": "Paclitaxel Eluting Balloon", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "PAD", 
            "stenting", 
            "angioplasty"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bonheiden", 
                        "country": "Belgium", 
                        "zip": "2820"
                    }, 
                    "name": "Imelda Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dendermonde", 
                        "country": "Belgium", 
                        "zip": "9200"
                    }, 
                    "name": "AZ Sint-Blasius Department of Vascular Surgery"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bad Krozingen", 
                        "country": "Germany", 
                        "zip": "79189"
                    }, 
                    "name": "Universit\u00e4ts Herzzentrum Freiburg Bad Krozingen Abteilung Angiologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "22527"
                    }, 
                    "name": "Angiologikum Hamburg Centre for Interventional Vascular Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04289"
                    }, 
                    "name": "Park-Krankenhaus Leipzig"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "REAL PTX - Randomized Evaluation of the Zilver PTX Stent vs. Paclitaxel-Eluting Balloons for Treatment of Symptomatic Peripheral Artery Disease of the Femoropopliteal Artery", 
        "overall_official": {
            "affiliation": "Park Hospital Leipzig", 
            "last_name": "Dierk Scheinert, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis.  Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.", 
                "measure": "Peak Systolic Velocity Ratio (PSVR)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis.  Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.", 
                "measure": "target lesion revascularization (TLR)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728441"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "MAE is defined as:\nDeath within 30 days of the index procedure or within 30 days of a target lesion revascularization (TLR)\nClinically-driven TLR, or\nMajor target limb amputation.", 
                "measure": "Major Adverse Events (MAEs)", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "measure": "All cause death", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "measure": "Target vessel revascularization (TVR)", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "description": "Clinically-driven TLR is defined as a reintervention performed for \u2265 50% diameter stenosis (confirmed by angiography) within \u00b1 5 mm proximal and/or distal to the target lesion after documentation of recurrent clinical symptoms of peripheral artery disease (PAD) following the initial procedure.", 
                "measure": "Clinically-driven target lesion revascularization (TLR)", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "description": "Major target limb amputation is defined as amputation of the target leg other than amputation of the toe(s).", 
                "measure": "Major target limb amputation within 6, 12 and 24 months.  Major target limb Major target limb amputation", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "description": "Sustained clinical improvement is defined as an improvement in the Rutherford category of one class compared to baseline in surviving patients who are free from major target limb amputation and free from target lesion revascularization (TLR).", 
                "measure": "Sustained clinical improvement", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "description": "Binary restenosis (Peak Systolic Velocity Ratio (PSVR) >2.4)of the target lesion at 6, 12 and 24 months or at the time of reintervention prior to any pre-specified time point.", 
                "measure": "Binary restenosis", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "description": "Walking capacity assessment by walking impairment questionnaire (WIQ) at 6, 12 and 24 months or at the time of reintervention prior to any pre-specified time point.", 
                "measure": "Walking capacity", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 24 months"
            }, 
            {
                "description": "Procedural success is defined as obtainment of < 30% residual stenosis on angiography by visual estimate.", 
                "measure": "Procedural success", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 24 months"
            }
        ], 
        "source": "Provascular GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "William Cook Europe", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Provascular GmbH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}